These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 31415565)

  • 1. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
    Mondal D; Kumar A; Sharma A; Ahmed MM; Hasnain MG; Alim A; Huda MM; Rahman R; Alvar J; Ahmed BN; Haque R
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007653. PubMed ID: 31415565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
    Goyal V; Das VNR; Singh SN; Singh RS; Pandey K; Verma N; Hightower A; Rijal S; Das P; Alvar J; Bern C; Alves F
    PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008429. PubMed ID: 32687498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case-control study protocol.
    Mondal D; Hasnain MG; Hossain MS; Ghosh D; Ghosh P; Hossain H; Baker J; Nath R; Haque R; Matlashewski G; Hamano S
    BMJ Open; 2016 May; 6(5):e010050. PubMed ID: 27188804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
    Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
    PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
    Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
    Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis.
    Pijpers J; den Boer ML; Essink DR; Ritmeijer K
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007173. PubMed ID: 30742620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic Arsenic Exposure and Risk of Post Kala-azar Dermal Leishmaniasis Development in India: A Retrospective Cohort Study.
    Das S; Mandal R; Rabidas VN; Verma N; Pandey K; Ghosh AK; Kesari S; Kumar A; Purkait B; Lal CS; Das P
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005060. PubMed ID: 27776123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-kala-azar dermal leishmaniasis in Nepal: a retrospective cohort study (2000-2010).
    Uranw S; Ostyn B; Rijal A; Devkota S; Khanal B; Menten J; Boelaert M; Rijal S
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1433. PubMed ID: 22206030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Effectiveness of Short-Course AmBisome in the Treatment of Post-Kala-Azar Dermal Leishmaniasis: A Prospective Cohort Study in Bangladesh.
    den Boer M; Das AK; Akhter F; Burza S; Ramesh V; Ahmed BN; Zijlstra EE; Ritmeijer K
    Clin Infect Dis; 2018 Aug; 67(5):667-675. PubMed ID: 29554244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
    Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
    Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh.
    Islam S; Kenah E; Bhuiyan MA; Rahman KM; Goodhew B; Ghalib CM; Zahid MM; Ozaki M; Rahman MW; Haque R; Luby SP; Maguire JH; Martin D; Bern C
    Am J Trop Med Hyg; 2013 Aug; 89(2):345-53. PubMed ID: 23817330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
    Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
    J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.
    Younis BM; Mudawi Musa A; Monnerat S; Abdelrahim Saeed M; Awad Gasim Khalil E; Elbashir Ahmed A; Ahmed Ali M; Noureldin A; Muthoni Ouattara G; Nyakaya GM; Teshome S; Omollo T; Ochieng M; Egondi T; Mmbone M; Chu WY; Dorlo TPC; Zijlstra EE; Wasunna M; Alvar J; Alves F
    PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011780. PubMed ID: 37988402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
    Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
    J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery.
    Hasan MM; Proma SB; Hossain MS; Arifuzzaman M; Islam N; Siddique MAB; Amiruzzaman
    BMC Infect Dis; 2023 Dec; 23(1):885. PubMed ID: 38110894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform.
    Singh-Phulgenda S; Kumar R; Dahal P; Munir A; Rashan S; Chhajed R; Naylor C; Maguire BJ; Siddiqui NA; Harriss E; Rahi M; Alves F; Sundar S; Stepniewska K; Musa A; Guerin PJ; Pandey K
    PLoS Negl Trop Dis; 2024 Apr; 18(4):e0011635. PubMed ID: 38626228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimony susceptible
    Ghosh S; Verma A; Kumar D; Deep DK; Ramesh V; Salotra P; Singh R
    Microbiol Spectr; 2024 Jun; 12(6):e0402623. PubMed ID: 38712926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Miltefosine Induced Reduced Male Fertility Capacity after Treatment of Post Kala-azar Dermal Leishmaniasis, Bangladesh.
    Basher A; Rashid MM; Habibullah AM; Nath R; Akter D; Chowdhury IH; Azim A; Nath P; Faiz MA
    Mymensingh Med J; 2019 Apr; 28(2):328-332. PubMed ID: 31086147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
    Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.